摘要
世界卫生组织(World Health Organization,WHO)于2010年发布了治疗药物敏感结核病(drug susceptible tuberculosis,DS-TB)的建议方案。这一方案广泛应用,但是在临床实际应用中发现部分患者因治疗时间较长未能完成6个月的治疗方案。基于两项Ⅲ期临床试验,WHO发布的2022年版指南首次增加了2021年最近一轮指南制定小组给出的相关循证建议,即推荐疗程4个月的方案治疗DS-TB。本文中,笔者就最新发布的2022年版指南对DS-TB的治疗方案进行解读,并提出展望。
In 2010,World Health Organization(WHO)issued recommendations for the treatment of drug susceptible tuberculosis(DS-TB).This treatment regimen is widely used,but in clinical practice,it is found that many patients fail to complete the 6-month treatment due to the long treatment time.Based on two phaseⅢtrials,for the first time,the 2022 WHO guidelines add to the evidence-based recommendations of the most recent 2021 guideline development panel,which recommended a 4-month regimen for DS-TB.In this article,the author interprets the treatment of DS-TB according to the latest 2022 guidelines.
作者
袁媛
卢水华
Yuan Yuan;Lu Shuihua(Shanghai Public Health Clinical Center,Fudan University,Shanghai 201508,China;National Clinical Research Center for Infectious Diseases/The Third People’s Hospital of Shenzhen/The Second Affiliated Hospital of Southern University of Science and Technology,Guangdong Province,Shenzhen 518112,China)
出处
《中国防痨杂志》
CAS
CSCD
2022年第11期1122-1125,共4页
Chinese Journal of Antituberculosis
基金
广东省感染性疾病〈结核病〉临床医学研究中心(2020B1111170014)
深圳市结核病临床医学研究中心(深科技创新〔2021〕287号)。
关键词
结核
肺
治疗应用
总结性报告(主题)
Tuberculosis,pulmonary
Therapeutic uses
Consensus development conferences as topic
